Market Dashboard
- You are here:
- Home
- Markets
- Market Dashboard
- Cipla Ltd.
NSE Symbol: | BSE Code: | ISIN: | Sector:
- Add to Portfolio
- Add to Watchlist
- Add to Alert
- Add to Message
| Change | Change % |
| 4.90 | 0.51% |
Updated:01 Jun, 2023, 15:59 PM IST |
|
| Change | Change % |
| 4.40 | 0.46% |
Updated:01 Jun, 2023, 16:01 PM IST |
|
Day's Range
52 Wk Range
Compare Price performance of vs. Peer Companies
From sector
Compare with Peers on Key Fundamentals and Financials
- SUNPHARMA
2.95% - DIVISLAB
1.90% - CIPLA
0.46% - DRREDDY
0.66% - CADILAHC
1.51% - ABBOTINDIA
-2.11% - ALKEM
0.52% - AUROPHARMA
1.85% - LUPIN
0.98% - TORNTPHARM
3.52% - BIOCON
1.51% - GLAXO
1.47% - PFIZER
0.35% - GLENMARK
2.23% - JBCHEPHARM
-0.18% - SANOFI
0.58% - PEL
0.51% - AJANTPHARM
1.03% - NATCOPHARM
0.46% - APLLTD
-1.34% - IPCALAB
2.23% - ERIS
1.41% - ASTRAZEN
5.12% - MERCK
-0.15% - GRANULES
2.13% - CAPLINLABS
1.78% - FDC
-1.58% - HIKAL
0.99% - LAURUSLABS
2.59% - NEULANDLAB
-0.22%
's Latest Research Report
| Brokerage/Analyst | Report Date | Call | Price@Call | Target | Current Status | Report |
|---|---|---|---|---|---|---|
| HDFC Securities - |
27-02-2020 | Buy | 421.35 | 495.00 | Closed | Details |
| Edelweiss - |
03-10-2019 | Buy | 416.50 | 500.00 | Closed | Details |
| Elara Capital - |
27-09-2018 | Buy | 665.35 | 680.00 | Closed | Details |
| Edelweiss - |
08-02-2018 | Hold | 605.00 | 560.00 | Target Hit | Details |
| CLSA - |
26-05-2017 | Sell | 486.90 | 525.00 | Target Hit | Details |
More from Research Reports »
Cipla's Key Fundamentals
| Parameter | Values |
|---|---|
| Market Cap (in ₹ Cr.) | 77,742.25 |
| Earning Per Share (EPS TTM) (₹) | 23.45 |
| Price To Earnings (P/E) Ratio | 41.14 |
| Book Value Per Share (₹) | 174.63 |
| Price To Books (P/B) Ratio | 5.52 |
| EBIT Margin (%) | 16.81 |
| PAT Margin (%) | 12.83 |
| ROCE (%) | 14.03 |
| PAT Growth (%) | 50.63 |
| Total Debt to Equity (D/E) Ratio | 0.01 |
More from Key Fundamentals »
Cipla's Financial Summary
| Parameter | MAR'18 (₹ Cr.) |
MAR'17 (₹ Cr.) |
YoY %Change |
|---|---|---|---|
| Balance Sheet: | |||
| Share Capital | 161.02 | 160.90 | 0.07% |
| Total Non-Current Liabilities | 202.95 | 191.34 | 6.07% |
| Total Current Liabilities | 2,731.70 | 2,555.83 | 6.88% |
| Total Liabilities | 17,048.17 | 15,547.68 | 9.65% |
| Total Non-Current Assets | 9,110.00 | 9,202.34 | -1.00% |
| Currents Investments | 1,039.74 | 638.18 | 62.92% |
| Cash and Bank | 227.53 | 58.46 | 289.21% |
| Total Current Assets Excluding Current Investments | 6,898.43 | 5,707.16 | 20.87% |
| Total Assets | 17,048.17 | 15,547.68 | 9.65% |
| Profit and Loss: | |||
| Gross Sales | 11,444.81 | 10,974.58 | 4.28% |
| Net Sales | 11,389.90 | 10,768.49 | 5.77% |
| PBIDT (Excl OI) | 2,195.55 | 1,596.26 | 37.54% |
| PAT | 1,468.52 | 974.94 | 50.63% |
More from Financial Summary »
Cipla's Shareholding Pattern
| Description | Percent of Share (%) |
|---|---|
| Promoters | 36.80 |
| Individuals | 20.13 |
| Institutions | 17.20 |
| FII | 16.07 |
| Govt. | 0.00 |
| Others | 9.80 |
More from Holding Pattern »
Cipla held by Mutual Fund Schemes
More from Mutual Fund Holding »
's Futures and Options Quotes
| Contract Expiry Date |
Type | Current price | Change | Change % | Premium / Discount |
|---|---|---|---|---|---|
| CIPLA 29-06-2023 |
FUTSTK |
969.10 | 10.30 | 1.07% | 4.35 |
| CIPLA 27-07-2023 |
FUTSTK |
967.60 | 11.00 | 1.15% | 2.85 |
| CIPLA 31-08-2023 |
FUTSTK |
967.10 | -1.90 | -0.20% | 2.35 |
More from Futures and Options Quotes »
Cipla is a pharmaceuticals company headquartered in Mumbai. Cipla has presence in over 80 countries, with its 43 manufacturing facilities and a portfolio including more than 1,500 products across a wide range of therapeutic categories. Cipla has a workforce of more than 23,000, according to its annual report 2017. In FY17, Cipla registered a net profit of Rs 975 crore over revenue of Rs 10,975 crore. As of September 2017, Cipla's promoter group held a 37.26 per cent stake in the drug maker while the remaining 62.74 per cent was with the public.
Its therapies portfolio includes women's health, devices, cardiovascular, children's health, dermatology & cosmetology, diabetes, HIV/AIDS, hepatitis, oncology, malaria, respiratory and urology.
Cipla shares
Shares are traded with symbol CIPLA on stock exchanges BSE and NSE.
History
Cipla was founded in 1935 by Dr K A Hamied.
BackgroundIn FY17, Cipla recorded a domestic of 10 per cent. It integrated its two acquisitions - InvaGen and Exelan - into its global mainstream operations.
Registered office
Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013